Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innate PharmaIPHA -14.84%39 Days Sales Outstanding is 61.23 as of Dec. 2025, which is 8% below its 10-year median of 66.28. GuruFocus rates IPHA with a GF Score™ of 39/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 838 Biotechnology companies, Innate Pharma ranks better than 56.09% on this metric.
Innate Pharma's average Accounts Receivable for the
six
months ended in Dec. 2025 was $0.44 Mil. Innate Pharma's Revenue for the
six
months ended in Dec. 2025 was $1.31 Mil.
Hence, Innate Pharma's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 61.23.
The historical rank and industry rank for Innate Pharma's Days Sales Outstanding or its related term are showing as below:
IPHA'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.52 Med: 66.28 Max: 229.67
Current: 61.29
During the past 13 years, Innate Pharma's highest Days Sales Outstanding was 229.67. The lowest was 11.52. And the median was 66.28.
IPHA's Days Sales Outstanding is ranked better than 56.09% of 838
companies
in the Biotechnology industry
Industry Median: 69
vs IPHA: 61.29
Innate Pharma's Days Sales Outstanding
increased
from Dec. 2024 (22.23) to Dec. 2025 (61.23).
Innate Pharma (NAS:IPHA) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Innate Pharma Days Sales Outstanding Related Terms
Innate Pharma Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Innate Pharma's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPHA vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Innate Pharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innate Pharma Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innate Pharma's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Innate Pharma's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innate Pharma (IPHA) has a Days Sales Outstanding of 61.23 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Innate Pharma and its competitors. This is near median its historical median of 66.28. Over the past decade, Innate Pharma's Days Sales Outstanding has ranged from 11.52 to 229.67. According to the industry distribution chart, Innate Pharma ranks #368 out of 838 companies in the Biotechnology industry, placing it in the top 43.9%.
Is Innate Pharma's Days Sales Outstanding too high?
Innate Pharma's current Days Sales Outstanding of 61.23 is near median its 10-year median of 66.28. Over the past 10 years, this metric has ranged from a low of 11.52 to a high of 229.67. The Biotechnology industry median Days Sales Outstanding is 69.00. Innate Pharma's value of 61.23 is 11.3% below this industry median. Based on the distribution chart, Innate Pharma ranks #368 out of 838 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Innate Pharma has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innate Pharma ranks #368 out of 838 companies for Days Sales Outstanding. This puts Innate Pharma in the upper half of its industry. The industry median Days Sales Outstanding is 69.00. Innate Pharma's value of 61.23 is 11.3% below this benchmark. Historically, Innate Pharma's own Days Sales Outstanding has ranged from 11.52 to 229.67 over the past decade. While the company's 10-year median is 66.28 vs. the industry median of 69.00, Innate Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.00, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innate Pharma's current Days Sales Outstanding of 61.23 is 11.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Innate Pharma and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innate Pharma's current Days Sales Outstanding is 61.23, which is near median its own 10-year median of 66.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $2.18 — trading 1353.3% above its estimated fair value. The current Days Sales Outstanding is 61.23, which is near median its 10-year median of 66.28 and 11.3% below the Biotechnology industry median of 69.00. Innate Pharma's overall GF Score™ is 39/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Innate Pharma (IPHA), the current Days Sales Outstanding is 61.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innate Pharma (IPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued.
The current stock price of $2.18 is trading 1353.3% above its estimated GF Value™ of $0.15.
GuruFocus considers Innate Pharma to be Significantly Overvalued.
Key valuation signals for IPHA:
Days Sales Outstanding: 61.23 (near median its 10-year median of 66.28)
GF Value™: $0.15 vs. price of $2.18 (1353.3% above fair value)
Industry Position: 11.3% below the Biotechnology median (#368 of 838)
No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
39GF Score
Get the complete analysis for IPHA
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPHA has been successfully added to your 
